The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000678392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/05/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Metabolic responses to fibre-rich meals in adults with metabolic syndrome
Scientific title
Postprandial glycaemic and triglyceride responses to fibre-enriched meals in adults with metabolic syndrome
Additional trial identifiers [1] 317134 0
NHMRC e-ASIA Grant ID: 2035876
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Metabolic syndrome 341699 0
Condition category
Condition code
Metabolic and Endocrine 337784 337784 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Brief name: Standardised fibre-enriched dietary challenge meals
The intervention for this study involves the administration of sequential fiber-enriched challenge meals (Intervention Meals) to adults with metabolic syndrome. Participants will consume these standardized meals to allow for the systematic measurement of postprandial glycaemic and triglyceride responses, specifically focusing on the monitoring of glucose and triglyceride levels. This exposure is designed to characterize individual physiological variations in blood sugar and lipid metabolism following the intake of fiber-rich dietary components.
During the 13-day study period, participants will consume a croissant breakfast (high-fat challenge meal) on Day 1 and Days 7–10. The croissant meal contains approximately 64 g carbohydrate, 38 g fat, and 12 g protein.
A muffin breakfast (high-carbohydrate challenge meal) will be consumed on Days 2–6. The muffin meal contains approximately 75 g carbohydrate, 18 g fat, and 6 g protein.
During Days 11–13, no breakfast will be provided and participants will consume their habitual breakfast without restriction.
Adherence to the intervention will be assessed according to the study schedule and dietary records.
To further define the exposure, the study includes a comprehensive assessment of participant characteristics that may influence these metabolic outcomes. This includes the collection of anthropometric measurements, habitual 3-day food intake, satiety via a Visual Analogue Scale (VAS), and physical activity levels. Additionally, biological profiling will be conducted through the analysis of gut microbiome 16S and metabolic SNPs (Single Nucleotide Polymorphisms).
The integration of these dietary interventions and biological measurements aims to identify how demographic and individual metabolic variations—ranging from body composition and lifestyle to genetic and microbial factors—dictate the diversity of postprandial responses to fiber in a population with metabolic syndrome.
Intervention code [1] 333899 0
Treatment: Other
Description of the comparator or control
No controlled group. This is a pre- and post-trial within group design.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345234 0
Postprandial glucose response
Timepoint [1] 345234 0
Days 1–13 continuous monitoring
Primary outcome [2] 345235 0
Postprandial triglyceride response
Timepoint [2] 345235 0
Day 1 and Day 7-10
Secondary outcome [1] 461990 0
nil
Timepoint [1] 461990 0
nil

Eligibility
Key inclusion criteria
Adults with metabolic syndrome, defined as meeting at least three of the following criteria:
(1) abdominal obesity (waist circumference greater than 102 cm in men or greater than 88 cm in women);
(2) elevated triglycerides (greater than or equal to 1.7 mmol/L) or treatment for elevated triglycerides;
(3) reduced HDL cholesterol (less than 1.03 mmol/L in men or less than 1.29 mmol/L in women) or treatment for low HDL;
(4) elevated fasting glucose (Fasting blood glucose 5.6–7.0 mmol/L);
(5) hypertension (SBP greater than or equal to 130 mmHg or DBP greater than or equal to 85 mmHg) or treatment for hypertension.
Participants must be able to comply with study procedures and have access to a mobile device or computer.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Does not have reliable access to the internet via a computer or mobile device
- Not fluent in English
- Current diagnosis of type 1 or type 2 diabetes, or on any diabetes medications except metformin
- Inpatient treatment for a psychiatric condition within the past 6 months, or currently receiving treatment for schizophrenia or other serious psychiatric illness
- Probable major depression, defined as a PHQ-8 score greater or equal to 10
- Pregnant women, planning a pregnancy in the next 24 months, given birth in the last 6 months, or currently breastfeeding
- Great or equal to 30 total days of oral corticosteroid use within the last year, history of solid organ transplant, or history of stem cell transplant
- Problematic use of alcohol and/or recreational drugs based on the ASSIST screening tool (score greater or equal to 27).
- Self-reported or known history of an eating disorder (e.g., binging and purging) in the past 5 years
- Use of weight loss medications (Qsymia, phentermine, etc.) or supplements in the last 3 months, or unwilling to abstain from taking weight loss medications or supplements during the study
- History of bowel resection surgery or bariatric surgery
- Participant does not have, or is unwilling to seek care from, a primary care physician at the time of enrollment
- Any medical condition known to influence the etiology of MetS as judged by the study physician (e.g., uncontrolled hypothyroidism, endocrine hypertension, etc)
- History of major cardiovascular illness, including a) stroke; b) myocardial infarction; c) congestive heart failure requiring hospitalization, or greater than NYHA heart failure class I; d) uncontrolled hypertension (SBP greater than 180 or DBP greater than 105); e) unstable angina; or f) other major cardiovascular illness which the site PI determines could limit ability to participate in the trial.
- Behavioral/logistical barriers to trial participation or engagement, e.g., a scheduled major surgery, scheduling difficulties, travel plans, moving outside the study area
- Cognitive impairment, defined by a Montreal Cognitive Assessment (MoCA) score less or equal to 25. The MoCA will be administered only when research staff suspect cognitive impairment
- Visual or hearing impairment
- Severe food allergies or food intolerances/preferences that preclude participation in the ELM program
- Currently taking or expecting to take any of the following exclusionary medications:
• Antiretroviral therapy (e.g., HAART)
• Weight loss medications
• Medications known to significantly influence weight or metabolic outcomes
• Diabetes drugs other than metformin
- Participation in any clinical trial, until at least six months following the end of the intervention phase.
- Cancer treatment within the last 6 months, excluding chemoprophylaxis or treatment for non-melanoma skin cancer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive statistics will be used to summarize participant characteristics and outcome measures. Changes in postprandial glucose and triglyceride responses will be analyzed using pair-wise t-test or repeated measures of variance providing a pass of normality test. Associations between metabolic responses and participant characteristics will be explored using regression models. Statistical significance will be set at p < 0.05.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321718 0
Government body
Name [1] 321718 0
National Health and Medical Research Council (NHMRC)
Country [1] 321718 0
Australia
Primary sponsor type
University
Name
University of Wollongong
Address
Country
Australia
Secondary sponsor category [1] 324548 0
None
Name [1] 324548 0
Address [1] 324548 0
Country [1] 324548 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320251 0
University of Wollongong Health and Medical Human Research Ethics Committee
Ethics committee address [1] 320251 0
Ethics committee country [1] 320251 0
Australia
Date submitted for ethics approval [1] 320251 0
24/11/2025
Approval date [1] 320251 0
09/02/2026
Ethics approval number [1] 320251 0
H2025-1520

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149894 0
Prof Xu-Feng Huang
Address 149894 0
Room 305, Building 32, University of Wollongong, Northfields Avenue, Keiraville, NSW 2522
Country 149894 0
Australia
Phone 149894 0
+61 02 4221 4300
Fax 149894 0
Email 149894 0
Contact person for public queries
Name 149895 0
Xu-Feng Huang
Address 149895 0
Room 305, Building 32, University of Wollongong, Northfields Avenue, Keiraville, NSW 2522
Country 149895 0
Australia
Phone 149895 0
+61 02 4221 4300
Fax 149895 0
Email 149895 0
Contact person for scientific queries
Name 149896 0
Xu-Feng Huang
Address 149896 0
Room 305, Building 32, University of Wollongong, Northfields Avenue, Keiraville, NSW 2522
Country 149896 0
Australia
Phone 149896 0
+61 02 4221 4300
Fax 149896 0
Email 149896 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.